Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9NP80
UPID:
PLPL8_HUMAN
Alternative names:
Intracellular membrane-associated calcium-independent phospholipase A2 gamma; PNPLA-gamma; Patatin-like phospholipase domain-containing protein 8; iPLA2-2
Alternative UPACC:
Q9NP80; A4D0S1; C9JZI4; O95035; Q8N3I3; Q9H7T5; Q9NR17; Q9NUN2; Q9NZ79
Background:
Calcium-independent phospholipase A2-gamma (iPLA2-gamma), also known as PNPLA-gamma and Patatin-like phospholipase domain-containing protein 8, plays a crucial role in cellular lipid metabolism. It catalyzes the hydrolysis of fatty acids from glycerophospholipids, regulating membrane properties and signaling pathways through the production of free fatty acids and lysophospholipids. Its activity is pivotal in the mobilization of arachidonic acid, a key mediator in eicosanoid signaling, and in mitochondrial bioenergetics.
Therapeutic significance:
Given its involvement in mitochondrial myopathy with lactic acidosis, a disorder characterized by muscle weakness and neural deafness, targeting iPLA2-gamma presents a promising avenue for therapeutic intervention. Understanding the role of Calcium-independent phospholipase A2-gamma could open doors to potential therapeutic strategies.